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Twelve patients with bone marrow failure , who were 
undergoing therapy with daily intravenous infusions of 
horse antithymocyte globulin, were studied for the de-
velopment of serum sickness. Eleven of 12 patients de-
veloped typical signs and sy mptoms of serum sickness 
8-13 days after the initiation of treatment. These in-
cluded fever, malaise, cutaneous eruptions, arthralgias, 
gastrointestinal disturbances, a nd lympha denopathy . 
Eleven of 12 patients developed high levels of circulat-
ing immune complexes during serum sickness. All 12 
patients also had concomitant decrea ses of serum C3 and 
C4 levels. In addition to urticarial and/or morbilliform 
eruptions, 8 of 11 patients also developed a serpiginous 
band of ery thema along the sides of the fingers, hands, 
toes, or feet as an early cutaneous sign of serum sickness. 
Direct immunofluorescence of lesional skin biopsies dur-
ing serum sickness revealed deposits of immunoglobulin 
or complement in the walls of small cutaneous blood 
vessels in 3 of 5 patients. These findings indicate that 
circulating immune complexes play a central role in the 
pathophysiology of human serum sickness. 
The fi rst detailed description of human serum sickness was 
presented by Clemens von Pirquet and Bela Schick in t heir 
classic monograph wri tten in 1905 ent it led "Die Serumkrank-
heit" or "Serum Sickness" [1] . In the early 1900's t hese 2 
physicians were attempt ing to use se rum therapy to control 
various infectious diseases. Serum therapy consisted of the 
injection of hyperimmune heterologous se rum into a human 
subject suffering from a pa rt icular disease. In t heir cases von 
Pirquet and Schick were using horse ant iserum to diphtheria 
organisms to t reat diphtheria infections in children. von Pir-
quet and Schick noted that s.c. injections of horse serum 
produced a reproducible reaction patte rn in many of their 
patients. This consisted of fever, malaise, cutaneous erupt ions, 
lymphadenopathy, a rthra lgias, leukopenia, and proteinuria 
which began 8- 12 days a fter injection of t he horse serum. They 
a lso noted t hat the incidence of serum sickness was related to 
t he amount of horse serum administered. Individua ls who re-
ceived 5-10 cc s.c. had an incidet:tce of serum sickness of 5-
10% while those who received la rge amoun ts of horse serum 
(up to 200 cc) had an incidence of serum sickness approaching 
90%. Alt hough von Pirquet and Schick suspected that serum 
sickness was a manifestat ion of an immune reaction of t he host 
to the foreign ant igens injected, the methodology needed to 
pursue this line of inquiry was not ava il able. 
Later, several large retrospective clinical studies of serum 
sickness confirmed the findings of von Pirquet and Schick 
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[2-4]. However, it was not unt il t he studies of Germuth et a! 
and Dixon et a l, using animal models of serum sickness, t hat 
insight into the pathophysiology of t his disease was achieved 
(5- 7]. These investigators found that foreign proteins injected 
into t heir animals resulted in a strong ant ibody response, and 
that the host antibody combined with t he injected ant igen to 
form circulating ant igen-antibody complexes. These immune 
complexes were capable of activating complement as well as 
causing t issue damage such as carditis, arteritis, and glomeru -
lonephrit is. These findings clearly indicated that circulat ing 
immune complexes mediated serum sickness in animals and by 
inference suggested that the same was t rue in humans. Since 
that ti me, numerous single case reports of serum sickness have 
been published but few patients have undergone an in-depth 
immunological analysis (8- 11]. 
In this study we present a prospective clinical and immuno-
logical study of serum sickness occurring in patients wit h bone 
marrow failure t reated with in fusions of horse ant ithymocyte 
globulin (ATG) (1 2]. 
MATERIALS AND METHODS 
Patients 
Twelve patients were admi tted to the Clinical Hematology Branch 
of the National Institu tes of Healt h. All patients had been diagnosed 
as having bone marrow fa ilure. Afte r obtaining informed consent, the 
patients were entered in to a protocol using i.v. in fusions of horse 
ant it hymocyte globulin (ATGAM , Upjohn Co., Ka lamazoo, Michigan) 
for t he t reatment of bone marrow fa ilure. The i.v. infusions were given 
over 5 h at a dosage of 15 mg/ kg/ day for 10 days. T he patients also 
received methylprednisolone 1 mg/ kg/ day which was increased to 1.5 
mg/ kg/ day during serum sickness. Blood samples were obtained before 
and afte r ATG t herapy as well as daily t hroughout its course. 
Immune Complex and Complement Assays 
The ' 25I-C 1q binding assay was performed as previously described 
[13). The upper limit of normal in the C1q-binding assay is 10%. T he 
Raji cell assay for IgG-containing circulat ing immune complexes was 
perfo rmed according to the method of Theo filopoulos [14] as modified 
by Hall [15). 
Assays for hemolytic C3 and C4 t ite rs were perfo rmed as previously 
described [16,17]. 
Plasma levels of C3a/ C3a des Arg were measured by a commercially 
available radioimmunoassay (Upjohn Diagnostics, Ka lamazoo, Michi-
gan). The range of normals in our laboratory is 90-880 ng/ ml. 
Direct Immunofluorescence 
Three-millimeter skin punch biopsies of early ( < 24 h ) lesiona l skin 
were obta ined in 5 patients and processed for routine direct immuno-
flu orescence. Four-micrometer cryostat sections were then stained wit h 
FITC-conjugated goat ant ihuma n lgG (1:80), lgA (1:20), lgM (1:20) , 
lgE (1 :20), C3 (1:20) , a nd fibrin (1 :20) (Tago, Inc., Burlingame, Cali -
fornia). Specimens were examined with a Leitz epifluorescence micro-
scope. 
Histopathology 
T hree-millimeter skin punch biopsies of cutaneous erupt ions occur-
ring during serum sickness were obtained in 5 patients, fixed in 10% 
neut ral fo rmalin, and processed for rout ine light microscopy. 
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RESULTS 
Clinical Ob:;erua.Lions 
All12 patients completed the 10-day course of ATG therapy. 
E leven of 12 patients developed the s igns and symptoms of 
serum sickness 8- 13 days after beginning ATG. These included 
fever, ma la ise, cutaneous eruptions, arthralgias, gastro in tes-
tinal disturbances, and lymphadenopathy (Table I). 
A variety of cutaneous eruptions were documented in these 
patients during ATG therapy. Eight patients developed an 
urticarial react ion to t he ATG in fusions very early (day 1- 3) 
in the ir treatment course. This eruption responded to therapy 
with antihistam ines and was clearly not a manifestation of 
se rum sickness. When serum sickness did occur in these pa-
tients, it was always associated with cutaneous eruptions. The 
onset of cutaneous eruptions assoc iated with serum sickness 
was closely re lated in t ime to t he onset of t he other manifes-
tations. The se rum sickness related erupt ions began on day 9.5 
± 2.6. F ive patients had only morbilliform eruptions wh ich 
began on the t runk as erythematous patches before spreading 
to involve the extemiti es. Five patients had both morbilliform 
and urticarial erupt ions during serum sickness and 1 patient 
had urticaria alone. 
In addition to t he urticarial and morbilliform e ruptions, 8 
patients a lso manifested an unusua l cutaneous s ign during 
serum sickness. This consisted of a se rpiginous band of ery-
thema a long the s ides of the fingers, hands, toes, and feet at 
the margin of pa lmar or planta r skin . The erythema was quite 
subtle, at first, but became more obvious as se rum sickness 
progressed. In many patients, because of their marked throm-
bocytopen ia, t he erythema was replaced by purpura. This band 
of erythema was in man y instances the ea rliest cutaneous 
manifestation of se rum sickness (Fig 1). 
Circulating Immune Complexes 
E levated leve ls of circulating immune complexes were found 
in 11 of 12 patients treated with ATG, as detected by the C1q 
TABLE I. Clin.ica.l si~:ns and symptoms in. II patients with serum 
sic/m ess 
F'ever 
Malaise 
Cutaneous erupt ions 
Arthralgias 
Gl distu rbances 
Lymphadenopathy 
100% 
100% 
100% 
55% 
45% 
18% 
Ftc l. The foot of a pat ient with serum sickness showing hemor-
rhage in a serpiginous band at the border of planta r skin . The hemor· 
rhage which occurred because of t his patient's marked thrombocyto-
penia was preceded by erythema in exactly the sa me distribution. 
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Ftc 2. Serum immune complexes, complement levels, a nd symp· 
toms in a patient with se rum sickness. A graph showing the time course 
of changes in C1q binding activity a nd C4 levels as well as the occur-
rence of dermatologic and rheumatologic disease in a representative 
patient with ATG- induced serum sickness. Va riations in height of bar 
graph showing dermatologic disease represent changes in disease se-
verity. 
TABLE II. Serum C3 profiles in patients treated with A TG 
Baseline C3 Nadir C3 
Patient concentration concentration Nadir day % Decrease (% of con· (% of con· in C3 
t rol) t rol) 
1 114% 10% 16 91% 
2 103% 15% 15 85% 
3 24% 0 9 100% 
4 94 % 31 % 10 67% 
5 28% 20% 9 29% 
6 68% 38% 11 44 % 
7 115% 63% 11 45% 
8 53% 0 10 100% 
9 65% 43% 4 34% 
10 21% 0 8 100% 
11 68% 18% 15 74% 
12 100% 11% 9 89% 
Mean 71 % 20.8% 10.6 71.5% 
so ± 34.5 ± 19.6 ± 3.4 ± 27.0 
binding assay. The rise and fa ll of immune complexes were 
closely correlated with the overall time course of serum sickness 
(Fig 2). The mean of pret reatment values of C1q binding 
activity for the 12 patients was 12.4 ± 7.2%. During serum 
sickness t he mean peak C1q binding level-reached 47.2 ± 13.5% 
on day 12.3 ± 2.3. A rise and fa ll of immune complexes were 
also detected using the Raji cell assay. In the seven patients 
studied, the mean baseline immune complex level was 0.94 ± 
0.29. This rose to a mean peak level of 1.47 ± 0.39 on day 10.1 
± 2.3. 
Complement Levels 
Serum C3 was measured in all patients (Table II) . Five 
patients began ATG therapy with normal C3 levels (> 90% of 
control) and 7 patients had decreased baseline C3 levels (< 
90% of control) . All 12 patients showed decreased C3 levels 
during serum sickness . The time course of C3 decreases closely 
paralleled the development of t he signs and symptoms of serum 
sickness and the appearance of circulating immune complexes. 
C3 decreases ranged from 29-100% of baseline levels and 
reached nadir values at day 10.6 ± 3.4. The mean decrease in 
C3 levels was 71.5 ± 27% (Table II). 
Serum C4 levels were also markedly depressed in all 12 
patients during serum sickness (Fig 2). The mean baseline C4 
level was 77.8 ± 36.8%. The mean nadir level of serum C4 
during serum sickness was 6.6 ± 8.5% which occurred on day 
July 1985 
TABLE III. Serum C4 profiles in patients treated with ATG 
Baseline C4 Nadir C4 
concentration concentration Nadir Day % Decrease PatienL (c%1 of con- (%of con- in C4 
trol) t.rol) 
1 62% 14% 16 77% 
2 54% 4% 13 93% 
3 132% 0 9 100% 
4 20% 1% 10 95% 
5 31% 25% 9 19% 
6 94% 10% 11 89% 
7 65% 19% 7 71 % 
8 60% 0 10 100% 
9 105% 3% 4 97% 
10 72% 0 8 100% 
11 138% 3% 15 98% 
12 100% 0 9 100% 
Mean 77.8% 6.6% 10.0 86.6% 
SD ± 36.8 ± 8.5 ± 3.3 ± 23.3 
10 ± 3.3. The mean decrease of se rum C4 was 86.6 ± 23.3 % 
(Table III) . Aga in the t ime course of C4 reductions correlated 
well wit h t he onset of clinical disease and the appearance of 
circulating immune complexes. 
Plasma levels of C3a/C3a des Arg were measured serially in 
4 patients. C3a/C3a des Arg is a cleavage fragment of C3 and 
is a potent a nap hylatoxi n. All 4 patients showed increases in 
plasma C3a levels during serum sickness. The mean pretreat-
ment baseline va lue of 11.5 ± 13.7 ,ug/ ml increased to a mean 
peak leve l of 42.8 ± 30.7 ,ug/ml on day 9.5 ± 5.3. 
Direct !mmu.n.ofluorescence 
Skin biopsies of cutaneous lesions less t han 24-h old were 
obtained in 5 patients. Of the 5 biopsies obtained during serum 
sickness, 3 revealed immunoreactants in t he walls of superficia l 
cutaneous blood vesse ls. IgM deposits were found in 3 patients, 
IgE and C3 in 2, and lgA in one. No deposits of IgG were found 
in any patients. 
H~stopathology 
Skin biopsies were obta ined from 5 patients during serum 
sickness. All patients were neut ropenic and thrombocytopenic. 
The biopsies showed only low grade perivascula r infiltrates of 
lymphocytes and histiocytes associated in some cases wi t h 
modest stromal edema. There was no ev idence of significan t 
vascular damage. 
DISCUSSION 
The constellation of s igns and symptoms t hat clinically de-
fine t he syndrome of se rum sickness were described in great 
detail by von P irquet and Schick at t he turn of the century, 
but t he pathophysiology of serum sickness remained speculative 
for many yea rs. The development fl f animal models of serum 
sickness in t he 1950's and 1960's provided ha rd evidence t hat 
not only was serum sickness immunologically mediated, but 
t hat circulating immune complexes played a cent ral role in its 
pathophysiology. In one such model, immunized rabbits were 
infused with radiolabeled bovine serum albumin (BSA) and the 
animals were monitored clinica lly and immunologically ove r 
t ime (7] . After undergoing ini t ial equilibration with the extra-
vascular space, t he serum concent ration of the BSA gradually 
decreased through degradative processes. However, on about 
day 8 after t he single injection of antigen, the levels of free 
BSA decl ined precipitously. At t hi s same time immune com-
plexes appeared in t he circulation, complemen t levels de-
creased, and the animals became ill. Antigen, ant ibody, and 
complement were ident ified at sites of t issue injury including 
t he kidney and blood vessels. These findin gs indicated t hat 
circulating immune complexes were importa nt in t he patho-
physiology of t his animal model of se rum sickness and sug-
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gested t hat t he same was true for human serum sickness. 
Although a number of case reports have appeared in which 
immunologic parameters have been exam ined, t here has been 
no large scale, prospective, detailed study of t he clinical and 
immunological events in human serum sickness un t il recent ly 
[12]. 
Our patients were infused with la rge amoun ts of horse IgG 
ranging approximately from 750 mg to 1.5 g per day for 10 
days. Eleven of 12 patients developed typical clinical manifes-
tations of serum sickness and did so in a time course remarkably 
similar to t hat described by von Pirquet and Schick. The serum 
sickness was self-limited and usually resolved severa l days after 
A TG t heapy ended. 
The cuta neous manifestations of serum sickness were of 
spec ial interest. They consisted mainly of morbilliform erup-
tions either alone or in conjunction with urticaria. Additionally 
a high percentage of t hese individuals developed an unusual, 
previously unreported erupt ion along t he sides of t he fin gers, 
hands toes and feet at t he margin of palmar or plantar skin . 
This ~rupti~n began as a subtle serpiginous band of erythema 
and progressed in t hese patien ts to become purpuric, presum-
ably secondary to their thrombocytopenia. The eruption in 
ma ny instances was the earliest cutaneous sign of serum sick-
ness. It appears to be a useful cutaneous marker for ATG-
induced serum sickness in particular , and we suspect for serum 
sickness in genera l. 
The finding t hat t hese patients developed large rises and 
falls in the levels of ci rculating immune complexes t hat paral-
leled t he clinica l manifestations of serum sickness suggests that 
t hese immune complexes cause clinical disease. This is further 
buttressed by t he parallel decreases in serum C3 and C4 levels 
during serum sickness presumably caused by activation of t he 
complement system by the circulating immune complexes. It 
was also interestinrr to find very high plasma levels of C3a. C3a 
is a potent anaphylatoxin capable of inducing urt icarial lesions 
when int roduced into human skin . The high levels fo und during 
serum sickness suggest t he C3a may play an import~nt role in 
t he cuta neous manifestations of serum Sickness. Fmally, t he 
detection of deposits of immunoglobulin and complement in 
t he walls of sma ll cutaneous blood vessels in a majority of the 
patients tested is further evidence t hat ~ ircu la~ing immu ne 
complexes also mediate t he cutaneous mamfestatwns of serum 
sickness. 
All of t hese· pat ients were receiving substantial amounts of 
systemic glucocorticoids before and during serum sickness, as 
part of t he investigat ive protocol._ In spite of t his, al_most all of 
the patients developed serum sickness. This mdicates t hat 
methylprednisolone in doses of 1 mg/kg/day did not prevent 
the development of serum sickness. It is possible, however, t hat 
t he rrlucocorticoid t herapy did decrease the severi ty of t he 
illne;s. It is also possible t hat t hese patients' underlying illness, 
bone marrow failure, and associated leukopenia and t hrombo-
cytopenia, may have also affected t heir ~ linic~ l _course. . 
These data provide t he first prospective chmcal and Immu-
nological analysis of serum sickness in man. T hey confirm in 
man t he immunological obse rvations made in animal models 
of t he disease and present a previously undescribed cutaneous 
sign of serum sickness. 
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